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eIF4E1b, closely related to the canonical translation initiation factor 4E (eIF4E1a), cap-binding protein is
highly expressed in mouse, Xenopus and zebrafish oocytes. We have previously characterized eIF4E1b
as a component of the CPEB mRNP translation repressor complex along with the eIF4E-binding protein
4E-Transporter, the Xp54/DDX6 RNA helicase and additional RNA-binding proteins. eIF4E1b exhibited
only very weak interactions with m7GTP-Sepharose and, rather than binding eIF4G, interacted with 4E-T.
Here we undertook a detailed examination of both Xenopus and human eIF4E1b interactions with cap
analogues using fluorescence titration and homology modeling. The predicted structure of eIF4E1b
maintains the α + β fold characteristic of eIF4E proteins and its cap-binding pocket is similarly arranged by
critical amino acids: Trp56, Trp102, Glu103, Trp166, Arg112, Arg157 and Lys162 and residues of the
C-terminal loop. However, we demonstrate that eIF4E1b is 3-fold less well able to bind the cap than
eIF4E1a, both proteins being highly stimulated by methylation at N7 of guanine. Moreover, eIF4E1b
proteins are distinguishable from eIF4E1a by a set of conserved amino acid substitutions, several of which
are located near to cap-binding residues. Indeed, eIF4E1b possesses several distinct features, namely,
enhancement of cap binding by a benzyl group at N7 position of guanine, a reduced response to
increasing length of the phosphate chain and increased binding to a cap separated by a linker from
Sepharose, suggesting differences in the arrangement of the protein's core. In agreement, mutagenesis of
the amino acids differentiating eIF4E1b from eIF4E1a reduces cap binding by eIF4E1a 2-fold,
demonstrating their role in modulating cap binding.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
The cap-binding protein eIF4E is central to protein
synthesis in eukaryotes. eIF4E is a small, approxi-
mately 25 kDa protein, whose structure resembles a
cupped hand formed by an eight-stranded antiparallel
β-sheet, with three α-helices on its convex side. The
eIF4E cavity specifically interacts with the m7G(5′)
ppp(5′)N cap (where N is typically G or A) added to
RNA polymerase II transcripts. The indol rings of
conserved tryptophans in eIF4E sandwich the N-
7-methyl guanine base via cation–π stacking interac-Authors. Published by Elsevier Ltd. T
rg/licenses/by/3.0/).tions that are stabilized by van der Waals contacts and
salt bridges with additional tryptophan and positively
charged residues [1,2]. eIF4E is a component of the
eIF4F complex, which also includes the large scaffold
protein eIF4G and the eIF4A helicase and promotes
translation initiation by mediating the interaction be-
tween mRNA and eIF4G that has additional factor
binding sites including that for themultisubunit complex
eIF3, thus enabling the recruitment of the small
ribosomal subunit to the 5′ end of mRNA [3,4]. eIF4E
is considered to be a proto-oncogene, since its
overexpression causes tumorigenic transformation ofhis is an open access article under the CC BY license
J. Mol. Biol. (2015) 427, 387–405
388 Cap-Binding Ability of eIF4E1bfibroblasts, and high levels of eIF4E have also been
implicated in autism-like behaviors [5–7].
Multiple eIF4E homologues have been identified in
vertebrates,Drosophilamelanogaster,Caenorhabditis
elegans, Leishmania major, Arabidopsis thaliana and
Schizosaccharomyces pombe, among others [8]. The
initial classification of eIF4E-family members focused
on their sequence similarity and conservation of the
characteristic tryptophan residues that are located
close by or form the active-site center (Trp43 and
Trp56, respectively). Accordingly, vertebrate eIF4Es
have been grouped into three classes: class I proteins
correspond to the canonical eIF4E protein (hereafter
called eIF4E1a); class II proteins, eIF4E2 or eIF4E
homologous proteins (4EHP), substitute tyrosine,
phenylalanine or leucine for the tryptophan residues,
while the class III proteins, eIF4E3, possess a
non-aromatic cysteine instead of a tryptophan in the
active site [8,9]. Structures of mammalian eIF4E1a,
eIF4E2 and eIF4E3 proteins resolved in NMR or
crystallographic studies show the characteristic α + β
domain representative of all three classes [1,2,10,11].
This domain is composed of an up to eight-stranded
β-sheet that forms the cap cavity, backed by three long
α-helices with a binding site for eIF4E protein partners,
including eIF4Gand the regulatory proteins 4E-BPand
eIF4E transporter protein (4E-T).
TheeIF4E-binding site in eIF4G,YXXXXLϕ (whereX
is any residue and ϕ is hydrophobic), is also present in
4E-BP proteins, small proteins that bind eIF4E1awhen
hypophosphorylated in non-proliferating cells, prevent-
ing protein synthesis. When nutrient levels are high,
4E-BP phosphorylation by mTORC1 kinase releases
eIF4E1a, enabling it to interact with eIF4G. Similarly,
4E-T sequesters eIF4E1a via this YXXXXLϕ motif to
reduce general translation, though when bound to
mRNA, 4E-T repression is eIF4E independent
[3,7,12,13]. eIF4E proteins vary in their abilities to
bind the cap, eIF4G and 4E-BP [9].
Our study focuses on eIF4E1b, a class I protein,
that is closely related to the canonical eIF4E1a
protein. eIF4E1b is an evolutionary conserved gene,
arising in Tetrapoda as a result of the ancestral
eIF4E locus duplication [14]. In contrast to the
ubiquitously expressed eIF4E1a protein, eIF4E1b
expression is confined to ovaries, oocytes and early
embryos in mice, zebrafish and Xenopus [14–17]. In
Xenopus oocytes, eIF4E1b was identified as a
component of the CPEB mRNP repressor complex
along with the eIF4E-binding protein 4E-T, the Xp54/
DDX6 RNA helicase and the RNA-binding proteins
Pat and Lsm14, as well as mRNAs containing 3′
untranslated sequences recognized by CPEB [17].
Interestingly, neither recombinant nor oocyte lysate
zebrafish and frog eIF4E1b proteins were able to
bind immobilized m7GTP in contrast to their eIF4E1a
counterparts, and rather than binding eIF4G,
eIF4E1b interacts with 4E-T [15,17]. Inactivation of
eIF4E1b in Xenopus oocytes by microinjection of aspecific antibody or morpholino accelerated meiotic
maturation of oocytes [14,17]. Moreover, the eIF4E1-
b-interacting partner, 4E-T, translationally repressed
bound reporter mRNA.We thus proposed a repressive
“closed loop” model for the silencing of CPEB target
mRNAs in oogenesis involving CPEB and hence 4E-T
binding to their 3′ untranslated regions and the
interaction between eIF4E1b and 4E-T precluding
productive binding of eIF4E1a to eIF4G [17,18].
Sequence-specific translational repression is the
critical gene expression regulatory mechanism in
early development where it dictates processes includ-
ing oocyte maturation, establishment of embryonic
axes and cell fate determination [19]. In addition to the
CPEB/4E-T/eIF4E1b complex, other cases that con-
form to the generic model that invokes cooperation of
RNA-binding proteins specifically bound to the 3′
untranslated region of mRNA with the cap-binding
eIF4E-family members to form a closed loop via an
intermediate protein such as 4E-T or their mutual
interaction have been described. As an example of the
latter, in Drosophila, translational control by 4EHP
generates protein gradients that are essential for
specifying the embryonic pattern. 4EHP is recruited to
cadual mRNA by Bicoid that binds simultaneously to
both 4EHPand the caudal3′untranslated region [4,19].
Translational regulation may be thus efficiently
realized by non-canonical eIF4E proteins, even those
that exhibit intrinsically low affinity for the cap structure,
such as eIF4E1b or 4EHP [10,17,20]. A better insight
into eIF4E-binding protein/eIF4E/mRNA complex for-
mation will enable a more complete understanding of
the mechanism of translational regulation including the
participation of different eIF4E proteins.
In this study, we optimized conditions to obtain
stable recombinant eIF4E1b that allowed us to
investigate its cap-binding properties in relation to its
canonical eIF4E1a counterpart, using both Xenopus
and human proteins. The fluorescence assay of
protein–ligand binding together with structural model-
ing showed conserved differences in amino acids and
structural features responsible for the weaker affinity
of eIF4E1b to N7-methyl cap analogues and, unex-
pectedly, an exceptionally higher specificity toward
N7-benzyl cap analogues. Altogether, our findings
provide the basis for reduced cap binding by eIF4E1b
proteins, characteristic of several cap-binding proteins
that mediate translational repression.Results
eIF4E1a and eIF4E1b are highly related proteins,
with conserved cap-binding residues, and
distinguishable by several distinct amino acids
First, we compared the sequences of eight pairs of
vertebrate eIF4E1a/eIF4E1b proteins (Fig. 1). The
Fig. 1. Amino acid sequence alignment of vertebrate eIF4E1a and eIF4E1b proteins of H. sapiens, M. musculus, X. laevis and X. tropicalis, D. rerio, B. taurus,
R. norvegicus, C. familiaris and G. gallus, performed with CLUSTALW2. Residues in red and blue show negatively and positively charged amino acids within the
N-terminus, respectively. The conserved amino acids that distinguish eIF4E1a (gray) and eIF4E1b (black) proteins are highlighted. The amino acids of the eIF4E1a
cap-binding pocket and binding sites for eIF4G/4E-BP proteins are marked with circle and triangle symbols, respectively, with green and magenta shading, respectively,
showing their conservation. Starred residues indicate the residues whose impact on cap binding we checked experimentally. Secondary structural elements of α-helices
(H1–H3) and β-strands (S1–S8) are shown according to the crystal structure of human eIF4E1a in complex with m7GTP or m7GpppA [2].
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390 Cap-Binding Ability of eIF4E1balignment indicates the α-helical and β-sheet regions
that form the core of eIF4E1a proteins and the
active-site residues, both for binding the 5′ cap, as
well as eIF4G and 4E-BP [1,2]. Xenopus and human
eIF4E1a share 84% identical residues, with the main
differences located at the N-terminus and a few
conservative point mutations dispersed through the
rest of the proteins. Importantly, all residues participat-
ing in binding the cap and eIF4Gare conserved (Fig. 1).
CLUSTALW2 analysis revealed greater than 50%
identity for all eIF4E1a/eIF4E1b pairs; in the case of
human and frog proteins, this is 61% and 68%,
respectively. Strikingly, the N-terminal sequences of
eIF4E1a and eIF4E1b proteins are distinct in all
examined organisms; in eIF4E1b, these vary some-
what in length and sequence but are consistently rich
in basic residues (blue in Fig. 1) in contrast to the
more acidic and conserved N-termini of eIF4E1a
proteins (red, Fig. 1). Stretches of basic residues,
such as seen in the N-terminus of Xenopus
eIF4E1b, can promote nuclear import; however,
eIF4E1b in Xenopus oocytes was found exclusively
in the cytoplasm [17].
Similarly to eIF4E1a, eIF4E1b proteins possess
the highly conserved middle and C-terminal regions
corresponding to the α + β domain characteristic of
eIF4E proteins. Interestingly, most of the residues
that compose the cap-binding pocket are conserved
in eIF4E1b (Fig. 1, highlighted with green). More-
over, the eIF4E-binding protein site on eIF4E1a,
formed by residues located within H1 andH2 helices
[1,2], is also largely conserved in eIF4E1b (Fig. 1,
highlighted in magenta). However, closer examina-
tion of the eIF4E1a/eIF4E1b sequences revealed a
set of 15 conserved and dispersed amino acid
changes, which distinguish the two protein families
and which are present largely in the loop regions
(colored gray/black in Fig. 1).
In summary then, sequence comparison between
eIF4E1a and eIF4E1b proteins confirmed the high
level of sequence identity/similarity in the middle and
C-terminal regions that comprise the cap-binding
pocket noted previously [8,15,17] and identified
conserved charge differences at their N-termini, as
well as a conserved set of discrete residue changes
scattered throughout the proteins.
Homology models of Xenopus eIF4E1a and
eIF4E1b proteins
The high level of sequence identity of Xenopus
proteins to human and mouse eIF4E1a, whose
structures are known, allowed us to obtain reliable
cap-free and cap-bound homology models. Struc-
tural models of cap-free eIF4E1b were built using
human apo eIF4E1a as a template (see Materials
and Methods for details) and cap-bound eIF4E1a
and eIF4E1b with the mouse crystal complex of
eIF4E1a–m7GTP as a template (Fig. 2 and Fig. S1).Models of XeIF4E1a and XeIF4E1b in complex with
m7GTP indicate that Trp56, Trp102, Glu103 and
Trp166 adopt the predicted spatial positions allowing
for interactionwith them7Gmoiety of the cap structure
(Fig. 2a and Fig. S1; here, we used XeIF4E1b
numbering that is the same as for heIF4E1a;
numbering of the XeIF4E1a sequence is shifted
backward by 4 amino acids relative to XeIF4E1b).
Polar and mostly charged amino acids including
Asp90, Arg112, Arg157 and Lys162 are found in the
vicinity of the phosphate chain and are able to form a
hydrogen bond network as in human eIF4E1a and
stabilize the XeIF4E1a and XeIF4E1b–cap com-
plexes. The C-terminal amino acids, Ala204, Thr205,
Lys206, Ser207 and Thr211, which interact with
adenosine in the complex heIF4E1a–m7GpppA [2],
are also mostly conserved in eIF4E1b except for
Thr211, which stabilizes the ribose ring of adenosine.
In humaneIF4E1b, Thr211 is replaced byalanine, and
in Xenopus, it is replaced by serine.
Although the model of apo XeIF4E1b adopts the
globular α + β domain, similarly to human eIF4E1a,
loops S3-S4 and S1-S2, containing the tryptophan
residues Trp56 and Trp102, as well as the S5-S6
and C-terminal loop, are moved away from the
cap-binding pocket (Fig. 2b; see Ref. [21]). In
response to the presence of m7GTP, they undergo
significant conformational changes approaching the
ligand to make electrostatic contact with it.
Altogether then, sequence identity and modeled
structures indicate the same protein fold in eIF4E1b
as in eIF4E1a and a similarly arranged cap-binding
pocket when proteins are in apo and cap-binding
forms. However, previous studies using zebrafish
and frog proteins showed that, while eIF4E1a binds
m7GTP-Sepharose efficiently, the eIF4E1b counter-
parts only do so weakly, if at all [15,17]. We therefore
used the fluorescence assay of protein–ligand
binding to assess the mode of cap binding of
eIF4E1b proteins in comparison with their eIF4E1a
homologues. Our analysis included human and
Xenopus proteins.
Stabilizing the conformation of apo XeIF4E1b
The time-synchronized fluorescence titration
method, widely used to determine the affinity
constants of cap–eIF4E complexes [20,22–26],
measures the quenching of the intrinsic fluorescence
of tryptophan residues due to cap binding (Fig. S2).
Knowledge of the equilibrium association constant
Kas enables the calculation of the free-energy
changes involved in the interaction between eIF4E
and ligand, according to the standard equation
ΔG° = −RTlnKas.
The untagged eIF4E1a and eIF4E1b proteins
were purified from Escherichia coli using the
procedures previously optimized for human and
mouse eIF4E1a [20]. Briefly, the proteins expressed
Trp 166 Glu 103
Trp 56
Asp 90
Arg 157
Trp 102 
Lys 162
Ser 207
Lys 206Ser 211
Ala 204
Thr 205
Arg 112
Leu 210
(a)
Trp 102 
S3-S4 
S1-S2 
S5-S6 
C-terminal
loop
Trp 56 
(b)
Fig. 2. Models of the structures of Xenopus eIF4E1b protein in apo and cap-bound form. The models were predicted by
MODELLER using human/mouse eIF4E1a as a template (PDB IDs: 2GPQ for apo and 1IPB for cap-bound eIF4E1a). (a)
eIF4E1b in complex with the m7GTP. The amino acids forming the cap-binding site are indicated (blue). (b) Structural
superimposition of apo (magenta) and m7GTP-bound (blue) Xenopus eIF4E1b showing rearrangements of loops that
compose the cap-binding site.
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GdnHCl, refolded by one-step dialysis and purified
to homogeneity by ion-exchange chromatography
(Fig. 3a). Although all four proteins were purified
from inclusion bodies with similar efficiency, the
refolding step revealed their diversity of conforma-
tional stability. In particular, the refolding efficiency of
Xenopus eIF4E1b was 5-fold lower than that of the
other proteins, resulting from significant precipitationkDa X
4E
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Fig. 3. Analysis of eIF4E1a protein conformational stab
determined for human (red) and Xenopus (black) eIF4E1a and
human and Xenopus eIF4E proteins by 15% SDS-PAGE and C
over time was determined for Xenopus eIF4E1a and eIF4E1b
(black) and in the presence only of m7GTP (red).during dialysis, likely caused by its conformational
instability and tendency to aggregation.
Under standard conditions used for cap-binding
titration, where the protein solution is automatically
stirred and the set temperature is controlled by a
thermocouple, the fluorescence intensity of eIF4E
proteins should be constant or decrease only slightly
during the course of the experiment. This was the
case for both eIF4E1a proteins, while theb)
ility. (a) Relative fluorescence intensity over time was
eIF4E1b proteins as indicated. Insert shows the analysis of
oomassie Blue staining. (b) Relative fluorescence intensity
in the presence of 5% or 10% glycerol in buffer as shown
392 Cap-Binding Ability of eIF4E1bfluorescence signal of heIF4E1b and XeIF4E1b
decreased by about 10% and 25%, respectively
(Fig. 3a). Changes in fluorescence reflect mainly the
rearrangements in tryptophan local environment,
which can be induced by motions of protein
structure [27] and/or protein aggregation. These
type of changes for eIF4E proteins are abolished
when bound to cap analogue that mimic their natural
ligand 5′ mRNA cap (Figs. 2b and 3b), likely due to
the closure and stiffening of the cap-bound protein
structure [10,21]. Since we aimed to investigate the
cap-binding process of different class I eIF4E
proteins based on fluorescence quenching, it was
essential to find conditions that stabilize the apo form
of XeIF4E1b.
The 27-amino-acid N-terminal region of eIF4E1a
linked to the globular α + β domain has been shown
to be unstructured and not involved in binding the
cap [2,21,28]. We therefore examined whether
XeIF4E1b may be stabilized by removing the
equivalent region, which is highly basic. First, we
checked that this truncation did not alter its weak
binding to cap-Sepharose (Fig. S3). We found,
however, that the XeIF4E1bΔN27 protein was
slightly more stable relative to the full-length protein
(Fig. 3). We next tested glycerol, which is commonly
used as a polar buffer component that changes the
protein solvation layer and strengthens its hydrophobic
core [29–31]. Indeed, buffer containing 10% glycerol
provided the conditions under which the fluorescence
signal of XeIF4E1bΔN27 did not decrease more than
10% (Fig. 3b). As expected, under cap-binding
conditions, which stabilize protein, such an effect
was no longer noticeable (Fig. 3b and Fig. S2b).
Using the intrinsically more stable Xenopus
eIF4E1a protein, we then tested whether glycerol
affects its cap-binding capability. Comparison of the
data obtained in the presence and absence of
glycerol showed that this additional buffer compo-
nent reduces the association constants of eIF4E1a–
cap complexes by up to 50% (Table 1, compare
columns 4 and 6). We therefore report below the
binding affinities of XeIF4E1a and its mutant version
(named X4E1a6, see later) in buffer with and without
glycerol, to compare results between human and
frog eIF4E1a and eIF4E1b proteins.
Cap-binding features of Xenopus laevis eIF4E1a
The purified eIF4E1a proteins were then analyzed
by the time-synchronized fluorescence titration
method using sets of cap analogues that differ in
N7 and/or N2 guanine modification status, their
phosphate chain length, the presence of a second
nucleotide and modifications on ribose, all of which
contribute to the binding affinity of the cap [20,22,23].
We will discuss in more detail these individual
contributions below when we contrast the two
families of cap-binding proteins. Overall, XeIF4E1abehaved very similarly in the cap-binding assay to
human and mouse eIF4E1a proteins, determined
previously [20,22]. Not surprisingly, given the high
level of sequence identity between human and frog
proteins (84%), they exhibited very similar cap-binding
affinities (Table 1). The association constants for
complexes of XeIF4E1a with various cap analogues
compared to the human protein differ by only
approximately 50%, and equally important, the
features of binding the 5′ mRNA cap are conserved
(Table 1, columns 1, 4 and 5). First, the contribution to
the Gibbs free energy of binding resulting from a
methyl group at N7 of guanine is themajor factor in the
cap-affinity of XeIF4E1a, as it is for heIF4E1a.
Second, the cap-binding site environments of both
proteins, as predicted from homology modeling (Fig.
S1), react in the same manner to ethyl and benzyl
substitutions at N7 of guanine (Tables 1 and 2). Third,
the energy gain resulting from the binding of
phosphate groups to the total energy of complex
(ΔG°) is the same as for human eIF4E1a (Table 2,
columns 1 and 3). Based on these experiments
together with the modeled structures, we propose
that, similarly to human eIF4E1a, XeIF4E1a in
complex with cap is stabilized by cation–π stacking
interaction of the three aromatic rings, Trp52/m7G/
Trp98, and by a network of charged residue
hydrogen bonds of the cap-binding pocket with
m7G and the phosphate chain (Fig. S1).
eIF4E1b proteins interact distinctly with
N7-modified guanine
As shown in Table 1, the Kas values of human and
Xenopus eIF4E1b for m7GTP are approximately
3-fold lower compared with their eIF4E1a counter-
parts. In the case of the human proteins, these values
are68.4 ± 5.1 μM−1 for eIF4E1aand22.0 ± 1.4 μM−1
for eIF4E1b. The data also show that interactions of
both eIF4E1a and eIF4E1b proteins are considerably
stabilized by the N7-methyl substitution of the cap
analogue. The change in standard free energy of
binding m7GTP by eIF4E1a (ΔΔG°) compared to GTP
is −4.55 kcal/mol for human and −4.20 kcal/mol for
frog (Table 2). In the case of human eIF4E1b, the
energy gain is somewhat lower and is −2.87 kcal/mol.
This difference not only is due to the weaker affinity of
eIF4E1b to m7GTP but also reflects its approximately
5-fold higher affinity to unmethylated GTP (Table 1).
For XeIF4E1bΔN27, the lower conformational stability
prevented the determination of association constants
for weakly binding ligands such as GTP or m7GMP.
Bearing in mind that the phosphate chain is not as
strongly stabilized in eIF4E1b as in eIF4E1a (see
below), we propose that the higher binding of GTP
arises from alterations in stabilizing the guanine ring in
the cap-binding site.
Replacing the N7-methyl group with the bulkier
ethyl group (et7GTP) decreased the association
Table 1. Equilibrium association constants, Kas, for complexes of human and Xenopus eIF4E1a and eIF4E1b proteins with
the indicated series of cap analogues
Cap analogue Kas (μM
−1)
− glycerol
Ratio
Kas
(h4E1a)
to Kas
(h4E1b)
Kas (μM
−1)
− glycerol
Ratio
Kas
(h4E1a)
to Kas
(X4E1a)
Kas
a (μM−1)
+ glycerol
Ratio Kas
a
(X4E1a) to
Kas
a
(X4E1bΔN27)heIF4E1a heIF4E1b XeIF4E1a XeIF4E1a XeIF4E1bΔN27
Mononucleotides modified at guanine ring
GTP 0.027 ± 0.001b 0.159 ± 0.040 0.17 0.031 ± 0.006 0.87 0.055 ± 0.021 — —
m7GTP 68.4 ± 5.1b 22.0 ± 1.4 3.11 42.8 ± 2.0 1.60 23.34 ± 0.88 7.80 ± 0.41 2.99
et7GTP 13.04 ± 0.31 7.34 ± 0.34 1.78 7.89 ± 0.57 1.65 4.97 ± 0.22 2.26 ± 0.20 2.20
bn7GDP 16.79 ± 0.56 35.4 ± 1.6 0.47 10.62 ± 0.98 1.58 6.04 ± 0.92 4.36 ± 0.18 1.38
m2,2,7GTP 0.362 ± 0.008 0.272 ± 0.009 1.33 0.295 ± 0.021 1.22 0.176 ± 0.011 0.253 ± 0.046 0.70
N7-methylated mononucleotides with increasing number of phosphate groups
m7GMP 0.78 ± 0.04b 0.628 ± 0.016 1.24 0.567 ± 0.012 1.37 0.256 ± 0.018 — —
m7GDP 17.76 ± 0.34b 7.64 ± 0.71 2.32 11.42 ± 0.50 1.56 5.97 ± 0.37 2.43 ± 0.15 2.45
m7GTP 68.4 ± 5.1b 22.0 ± 1.4 3.11 42.8 ± 2.0 1.60 23.34 ± 0.88 7.80 ± 0.41 2.99
m7Gp4 419 ± 23 89.6 ± 4.0 4.68 268 ± 10 1.57 151.1 ± 8.6 43.0 ± 2.0 3.51
m7Gp5 547 ± 31 146.6 ± 9.9 3.73 378 ± 44 1.44 230 ± 31 65.6 ± 4.2 3.50
Dinucleotides
m7GpppG 5.94 ± 0.39b 3.53 ± 0.11 1.68 3.98 ± 0.11 1.49 2.291 ± 0.065 0.883 ± 0.032 2.59
m7GpppA 3.97 ± 0.21b 2.158 ± 0.053 1.84 2.015 ± 0.028 1.97 1.22 ± 0.053 0.615 ± 0.042 1.99
m7Gpppm2′-OG 4.77 ± 0.13 3.568 ± 0.071 1.34 — — 2.189 ± 0.026 — —
m7,2′-OGpppG 6.13 ± 0.34b 4.63 ± 0.12 1.32 — — 1.96 ± 0.24 — —
a Measurements were carried out in 10% glycerol whose presence in the buffer decreases the cap affinity to protein almost 2-fold.
b Data were taken from Ref. [20].
393Cap-Binding Ability of eIF4E1bconstants of both eIF4E1a proteins approximately
5-fold and of both eIF4E1b proteins 3-fold (Table 1).
A distinct effect was observed for N7-benzyl deriv-
ative. While benzyl substitution (bn7GDP) did not
influence eIF4E1a binding (compared with m7GDP),
it increased the association constants of human and
Xenopus eIF4E1b complexes with cap by approxi-
mately 5- and 2-fold, respectively. The crystalTable 2. Changes in the standard Gibbs free energy, ΔΔGo,
mRNA cap to the binding free energy of eIF4E–cap complexe
ΔΔGo (kcal/mol)
− glycerol
heIF4E1a heIF4E1b
Modifications on the guanine ring
GTP → m7GTP −4.555 ± 0.050 −2.87 ± 0.15
GTP → et7GTP −3.590 ± 0.028 −2.23 ± 0.15
m7GTP → et7GTP 0.965 ± 0.045 0.639 ± 0.045
m7GDP → bn7GDP 0.033 ± 0.022 −0.893 ± 0.060
m7GTP → m2,2,7GTP 3.052 ± 0.045 2.557 ± 0.041
Elongation of the phosphate chain
m7GMP → m7GDP −1.820 ± 0.028 −1.455 ± 0.056
m7GDP → m7GTP −0.785 ± 0.045 −0.616 ± 0.065
m7GTP → m7Gp4 −1.055 ± 0.054 −0.817 ± 0.044
m7Gp4 → m
7Gp5 −0.155 ± 0.046 −0.287 ± 0.047
Addition of the second nucleotide and methylation of the ribose ring
m7GTP → m7Gp3G 1.423 ± 0.058 1.065 ± 0.040
m7GTP → m7Gp3A 1.658 ± 0.053 1.352 ± 0.039
m7Gp3G → m
7,2′-OGp3G −0.018 ± 0.050 −0.157 ± 0.022
m7Gp3G → m
7Gp3m
2′-OG 0.128 ± 0.041 −0.006 ± 0.021
a Refers to measurements carried out in 10% glycerol.structure of human eIF4E1a with bn7GMP showed
that the cap-binding pocket is relatively flexible and
capable of conformational changes. When binding
the benzyl group, the side chain of Trp102 flips about
180° exhibiting the amino group of its indole ring to
the solvent, placing the benzyl ring in the hydropho-
bic vicinity of Trp166, His200 and Trp102 [32]. In
contrast to eIF4E1a whose conformational changesshowing the contribution of structural elements of the 5′
s
ΔΔGoa (kcal/mol)
+ glycerol
XeIF4E1a XeIF4E1a XeIF4E1bΔN27
−4.20 ± 0.12 −3.52 ± 0.23 —
−3.21 ± 0.13 −2.62 ± 0.23 —
0.984 ± 0.050 0.900 ± 0.035 0.722 ± 0.059
0.042 ± 0.059 −0.006 ± 0.096 −0.341 ± 0.044
2.897 ± 0.051 2.844 ± 0.042 2.00 ± 0.11
−1.748 ± 0.028 −1.832 ± 0.054 —
−0.769 ± 0.037 −0.794 ± 0.043 −0.679 ± 0.048
−1.067 ± 0.035 −1.087 ± 0.040 −0.994 ± 0.041
−0.202 ± 0.071 −0.244 ± 0.086 −0.246 ± 0.046
1.382 ± 0.032 1.351 ± 0.028 1.268 ± 0.037
1.779 ± 0.029 1.717 ± 0.033 1.479 ± 0.050
— 0.091 ± 0.074 —
— 0.026 ± 0.018 —
Fig. 4. The influence of phosphate groups on the
stability eIF4E1b–cap analogue complexes relative to
eIF4E1a–cap complexes, described as the ratio of
Kas(eIF4E1a) to Kas(eIF4E1b). The resultant charges of
cap analogues at given pH values were estimated from
experimental pKa1 values for dissociation of the N
1
proton of N7-methylguanosine and from the experimental
pKa2 values for the dissociation of the second proton of
the terminal phosphate group [33,34].
394 Cap-Binding Ability of eIF4E1bdid not significantly alter cap analogue complex
formation, comparing ΔΔG° of m7GDP with
bn7GDP, in the case of eIF4E1b, this substitution
resulted in considerable cap-binding enhance-
ment, with energetic gains of ΔΔG° = −0.89 and
−0.34 kcal/mol in the case of the human and
Xenopus protein, respectively (Table 2). These data
strongly suggest that the eIF4E1b cap cavity is not as
compact as in eIF4E1a since it is more able to
accommodate cap analogues with ethyl and benzyl
substitutions at the N7 position of guanine.
We also examined whether eIF4E1b could bind
the hypermethylated cap structure, m2,2,7GTP,
present in the uridine-rich small nuclear RNAs
involved in splicing and present at the 5′ end of
some nematode mRNAs [35]. The affinity of
eIF4E1b to m2,2,7GTP is weak and is the same
order of magnitude as for eIF4E1a, Kas ~ 0.3 μM
−1
(Table 1). The recently resolved structure of Ascaris
suum eIF4E with m7GTP and m2,2,7GTP shows that
the addition of two methyl groups at the N2 position
disrupts only the hydrogen bond between the N2
guanine base and the carboxyl group of Glu116
(human equivalent of Glu103) from the whole
network of cap–protein interactions. Unlike the
methyl group at position N7 in the cap structure
that faces inward to the core of eIF4E1a, the two
methyl groups at N2 are exposed to the solvent [25].
Altogether, eIF4E1b binds the cap analogues
approximately 3-fold less efficiently than eIF4E1a,
and for all tested proteins, the methyl group at N7 of
guanine is the major contributor to the protein's capaffinity. The enhanced binding of eIF4E1b to
bn7GDP in contrast to eIF4E1a indicates that the
base of the eIF4E1b cleft formed by the protein core
is more flexible and capable of forming non-specific
interactions with groups larger than methyl.
Weaker influence of phosphate groups on
stabilization of eIF4E1b–cap complexes
In addition to the positively charged 7-methylgua-
nine moiety, the negatively charged phosphate chain
is of primary importance for specific interactions of the
cap with eIF4E. The α, β and γ phosphates interact
with Arg112, Arg157 and Lys162 (heIF4E1a number-
ing) located in the S4 and S6 strands and the S5-S6
loop to stabilize the complex (Fig. 1; see Refs. [1] and
[2]). Further extending the chain with δ and ε
phosphate groups indicated the involvement of the
C-terminal loop (S7-S8) in the stabilization process
[23].
We observed that, for human and frog eIF4E1a/
eIF4E1b proteins, each added phosphate increases
the stability of protein–cap binding. However, this
increase of Kas values with longer phosphate chains
is consistently lower in the case of both eIF4E1b
proteins relative to their eIF4E1a counterparts (Fig. 4
and Table 1). For example, in the case of human
proteins, the energetic gain of binding the second
phosphate that makes a salt bridge with Lys162 and
a hydrogen bond with Arg157 is −1.8 kcal/mol for
eIF4E1a and −1.5 kcal/mol for eIF4E1b (Table 2),
while in case of the third phosphate, which forms a
hydrogen bond with Arg112, it is −0.8 kcal/mol for
eIF4E1a and −0.6 kcal/mol for eIF4E1b and likewise
for the fourth and fifth phosphates (Table 2 and
Fig. 4). The reduced sensitivity of eIF4E1b
proteins to the phosphate groups when binding
the cap analogues may reflect the changes in
amino acids in its C-terminal loop compared to
eIF4E proteins.
Biophysical studies with murine eIF4E(28–217)
showed that the S5-S6 loop (157–160) and the
C-terminal loop (198–213), regions that close up the
cap-binding pocket, have a significant influence on
binding the phosphate chain. Replacement of
Lys159 by neutral amino acids, such as alanine
and/or introduction of negative charge in position
209 by phosphorylation of Ser or its mutation to Asp
or Glu, reduced the affinity of the protein to cap
analogues having two or more phosphate groups
[23]. While the point mutations decreased Kas of
meIF4E(28–217) to m7GTP 3-fold, truncation of the
C-terminus [meIF4E(28–204)] reduced binding up to
5-fold [36]. Sequence alignment of vertebrate
eIF4E1a/eIF4E1b proteins shows that, while there
are no changes in the S5-S6 loop, the C-terminal
loop distinguishes the two families (Fig. 1). Specif-
ically, Thr210 and Thr211 are replaced with Leu
and Ser(Xenopus)/Ala(human), respectively.
395Cap-Binding Ability of eIF4E1bAdditionally, Gly in position 208 is substituted with
Ser in Xenopus and Asn in human proteins. Given
that the C-terminus significantly affects the binding of
eIF4E1a with the cap phosphate chain [23,36], we
propose that the presence of amino acids with
longer, polar side chains instead of Gly along with
the additional hydrophobic substitutions within the
C-terminal loop results in the weaker stabilization
of the eIF4E1b–cap complex by the phosphate
chain.
2′-O- ribose methylation does not enhance
eIF4E1b cap affinity
Our previous biophysical studies have revealed
that mammalian eIF4E1a proteins bind all of the
dinucleotide triphosphate cap analogues, m7GpppN
(where N is any nucleotide) from 10- to 30-fold
weaker than m7GTP, with even lower Kas values
than those observed for eIF4E1a–m7GDP com-
plexes [22,23]. Addition of the next nucleotides to the
cap analogue structure slowly restored the Kas value
to the level observed for m7GTP [36]. The same
destabilizing effect by the second nucleotide in the
cap analogue was observed for human andXenopus
eIF4E1b proteins (Table 2). As previously reported
[22,23], the presence of the second nucleotide
reduces the negative charge of the phosphate
chain and destabilizes the intermolecular contacts
between m7Gppp and eIF4E1a cap-binding resi-
dues. We suspect that the same mechanism is
observed for eIF4E1b; however, the energy change
resulting from the presence of the second nucleotide
is slightly smaller (0.1–0.35 kcal/mol) for eIF4E1b
than for eIF4E1a.
mRNA in higher eukaryotes is methylated at the
2′-O- ribose of the first and sometimes also the
second transcribed nucleotide [37,38]. The role of
these additional groups is still elusive. Our data for
eIF4E1a/eIF4E1b proteins with dinucleotides
(m7GpppN) further methylated at the first or second
nucleotide on the ribose ring do not reveal any
significant differences in binding compared with their
unmethylated versions (Tables 1 and 2; see Refs.
[22] and [39]), further indicating that neither 2′OH
groups nor their methylated forms interact with
eIF4E and remain solvent exposed [1,2].
Residues distinguishing eIF4E1a and
eIF4E1b–cap interactions
Our analysis of vertebrate eIF4E1a and eIF4E1b
sequences identified the amino acids that consis-
tently differentiate the two groups of proteins (Fig. 1).
Moreover, the three-dimensional model structure of
XeIF4E1b with m7GTP showed that some of these
residues are proximal to the amino acids that bind
the cap (Fig. 5a). These include Ser86(Met),
Ser87(Pro), Ser105(Glu), Arg106(Lys), Ala199(Ser),Leu210(Thr) and Ser211(Thr) (XeIF4E1b number-
ing, in brackets are shown the eIF4E1a amino
acids). We hypothesized that these residue changes
in eIF4E1b are a significant factor in its lower
cap-binding affinity. The presence in eIF4E1b of
Ser105 and Arg106 instead of Glu and Lys may
directly influence the position of Trp102 and hence
modify the stacking interaction with the cap.
Additionally, Ala199 in place of Ser may induce
changes in the orientation of the Trp102 indole ring
by influencing the position of His200 located close to
Trp102. Furthermore, cap-binding stacking interac-
tion may be weakened by changes of the Trp56
environment, resulting from alterations in the posi-
tion of Phe48 likely induced by the presence Ser86
and Ser87 instead of Met and Pro, respectively.
Replacement of Thr in positions 210 and 211 by Leu
and Ser is also likely to be important, as they are
located in the C-terminal loop responsible for
binding the phosphate chain and second cap
nucleoside.
We tested the effect on cap-binding activity of
these positions in the fluorescence assay with six
mutated recombinant versions of Xenopus eIF4E1a
(Fig. S4). The amino acids were introduced in
XeIF4E1a sequentially in the order: E101S/K102R/
S195A/M82S/T206L/T207S (numbering of the XeI-
F4E1a sequence is shifted backward by 4 amino
acids relative to XeIF4E1b). The mutants were
named with the last digit indicating the number of
changed positions, for example, X4E1a2 possesses
2 mutated positions. Circular dichroism (CD) analy-
sis indicates that these mutations do not change the
secondary structure content of XeIF4E1a as the
profile of far-UV CD spectra is the same for wild type
and mutant protein possessing all six substitutions,
X4E1a6 (Fig. 5b). The fluorescence titration data
shown in Fig. 5c and Table S1 indicate that when all
six residues were replaced, the association constant
measured with m7GTP decreased by 50% com-
pared to wild-type XeIF4E1a. The biggest contribu-
tion to the weaker cap binding of XeIF4E1a, in each
case about 20%, resulted from changing Glu101 to
Ser and Thr206 to Leu coupled with Thr207 to Ser,
with the remaining mutations having only minor
effects. Comparison of human apo eIF4E1a to the
cap-bound form shows that Trp102 (Trp98 in
XeIF4E1a) rotates into the cap-binding site and
nearby residues also undergo conformational rear-
rangements [21]. Glu101 is a solvent-accessible
amino acid and is proximal to Trp98 in the S3-S4
loop. Its evident effect on the binding affinity of
XeIF4E1a when mutated to Ser demonstrates that
properties of the S3-S4 loop amino acids influence
the orientation of the Trp98 indole ring that stacks
with 7-methylguanine. Attenuation of the cap-binding
affinity of XeIF4E1a resulting from mutating Thr206
and Thr207 is consistent with our results mentioned
above showing significant influence of C-terminal
(a) (b)
(c)
(d)
Fig. 5. (a) Homology model of eIF4E1b in complex with m7GTP. The residues forming the cap-binding site are indicated
(blue). Amino acids conserved in eIF4E1b and distinct to those in eIF4E1a proteins positioned in the neighborhood of the
cap-binding site are highlighted in red. Residues mediating cap binding that influence positions of Trp56 and Trp102 are
indicated in purple. (b) Far-UV CD spectra of XeIF4E1a and X4E1a6 performed at two protein concentrations: 5 and
10 μM. (c) Influence of mutations in XeIF4E1a on association constants. The mutations that introduce XeIF4E1b residues
into XeIF4E1a are listed in brackets under the name of mutants, with the amino acids that directly interact with the cap
marked below. (d) The equilibrium association constants, Kas, for complexes of XeIF4E1a, its mutated form X4E1a6 and
XeIF4E1b ΔN27 with m7GDP and bn7GDP.
396 Cap-Binding Ability of eIF4E1bloop residues on binding phosphate and the second
nucleotide.
We also compared the cap-binding properties of
X4E1a6 to those of XeIF4E1bΔN27 (Fig. 5d, Table 1
and Table S1). Though the changed residues in
X4E1a6 reduced its cap affinity almost 2-fold thus
resembling XeIF4E1b, however, they did not alter itssensitivity to the benzyl cap analogue. In contrast to
eIF4E1b showing increased binding toward bn7GDP,
X4E1a6 binds bn7GDP similarly to m7GDP, as did
wild-type XeIF4E1a (Fig. 5d). We conclude that the
introduced mutations do not impact on the core of the
protein being able to accommodate the benzyl group
but do influence stacking interaction with guanine and
397Cap-Binding Ability of eIF4E1bare responsible, in large part, for the reduced affinity of
eIF4E1b to the cap.
Cap-Sepharose binding assays
Previously, we and others found that eIF4E1b,
whether in cell lysates or in recombinant form, bound
only very weakly to cap-Sepharose, if at all [15,17]. In
agreement, our quantitative assays show that, in
solution, eIF4E1b binds the m7GTP cap analogue
lesswell than eIF4E1a, though the effect is only 3-fold,
less pronounced than predicted by these earlier
studies (Table 1). However, the affinity of the
immobilized cap analogue may differ significantly
from its free counterpart due to the coupling step
generating possible steric hindrance by close
proximity of the cap to the bulky Sepharose bead
[40]. To examine this possibility, we performed
cap-Sepharose assays using controlGTP-Sepharose,
m7GTP-Sepharose and m7GpCH2ppA-Sepharose
[40] with the use of oocyte lysate and recombinant
proteins. m7GpCH2ppA-Sepharose is a modified form
of m7GTP-Sepharose with a hexylene spacer linking
the cap to the resin (Fig. 6c). Lysates were prepared
from mid-stage Xenopus oocytes, when the levels of
eIF4E1a and eIF4E1b proteins are approximately
equal, as judged by Western blot analysis [17], and
portions were bound to the three matrices, which were
washedandboundproteins elutedwith 70 μMm7GTP
and subsequently with SDS buffer (Fig. 6a). A low
concentration of GTP (0.1 mM) was included in all the
buffers, to minimize non-specific binding. Fractions of
load, flow-through and bound proteins were assessed
by Western blotting and a pan-eIF4E1 antibody
(Fig. 6a). As expected, we did not observe any oocyte
protein binding to GTP-Sepharose, and in the case of
m7GTP-Sepharose, eIF4E1a was specifically eluted
from the matrix by free m7GTP and very much less
eIF4E1b as seen before [17]. With m7GpCH2ppA-
Sepharose, however, while similar amounts of
eIF4E1a and eIF4E1b were eluted with m7GTP,
SDS buffer eluted considerable amounts of eIF4E1b,
as well as eIF4E1a, compared to those seen with
m7GTP-Sepharose (Fig. 6a). In the case of recombi-
nant proteins, equal amounts were loaded onto the
Sepharose beads, and the washed and bound
proteins were eluted with 100 μM m7GTP and then
with 0.2% SDS prior to SDS-PAGE and Coomassie
Blue staining. The higher concentration of freem7GTP
compared to the oocyte assay allowed efficient elution
of eIF4E1a from these matrices but any weak release
of eIF4E1bwithm7GTPwas under the sensitivity level
of Coomassie detection. As for the oocyte assay,
SDS eluted considerable amounts of eIF4E1b from
m7GpCH2ppA-Sepharose (Fig. 6b). Though the rea-
son for the ability of SDS, and not cap analogue, to
release eIF4E1b is not clear, we conclude that
eIF4E1b–cap interactions can be enhanced by placing
a linker between m7GTP or m7GpppN and theSepharose bead. Since it already binds the cap better,
such an enhancement is also seen with eIF4E1a to a
lesser extent. The routine cap-Sepharose assay may
therefore be misleading with regard to cap-binding
capacities of proteins, in the absence of quantitative
affinity assays, ormodified capmatrices. Nevertheless,
our results suggest, once again, significant differences
between eIF4E1a and eIF4E1b interactions with the
cap.Discussion
Our experimental data and homology modeling,
summarized here and discussed below, demonstrate
shared and distinct features of cap binding by human
and Xenopus eIF4E1b proteins. eIF4E1a and
eIF4E1b proteins are highly related, both at the
sequence level and at the structural level, with
conserved cap-binding residues, as are those that
associate with eIF4G and 4E-BP. However, several
distinct conserved amino acid changes distinguish the
two families, modeled to be in the vicinity of residues
that bind the cap and in the C-terminal loop. eIF4E1b
binds m7GTP 3-fold less well than eIF4E1a, and the
N7-methyl group is a crucial contributor to cap
recognition by both proteins. However, in contrast to
eIF4E1a, benzyl substitution at N7 guanine enhances
affinity to eIF4E1b, suggesting that its core cap cavity
is less compact. Another difference between the two
class I families is that the complexes of eIF4E1b
proteins with cap analogues are less stabilized by
lengthening of the phosphate chain as seen for
eIF4E1a, possibly linked to differences in certain
C-terminal loop residues. Neither eIF4E1a nor
eIF4E1b proteins are affected by 2′O ribose methyl-
ation, whether of first or of second cap analogue
nucleotide. Interestingly, mutagenesis of several
distinguishing residues in XeIF4E1a to make it
resemble XeIF4E1b did indeed reduce its cap affinity
by approximately 50%, verifying the influence of
certain amino acids on those that bind the cap, as
well as C-terminal residues. However cap binding of
mutant X4E1a6 was not enhanced by benzyl at N7,
implying that the changes did not loosen its cap
cavity's compactness. Last, we showed that eIF4E1b
binding to cap-Sepharose can be specifically en-
hanced by introducing a linker between the cap
analogue and the Sepharose bead.
eIF4E1b, cap binding and implications for the
role of additional residues in cap affinity
Clearly, eIF4E1b similar to eIF4E1a shares the
basic mechanism of binding the 5′ mRNA cap based
on specific recognition of N7-methylguanine, princi-
pally mediated by two tryptophan residues and
interactions with the phosphate chain by positively
charged amino acids. However the 30–40%
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Fig. 6. Cap-Sepharose binding assays. (a) Lysates from mid-stage Xenopus oocytes were analyzed by affinity
chromatography with control GTP-Sepharose, m7GTP-Sepharose and m7GpCH2ppA-Sepharose. Aliquots of load (L),
flow-through (FT), wash (lanes 1–3), m7GTP elution (lanes 4 and 5) and final SDS-sample buffer (SDS) fractions were
analyzed by Western blotting using an-eIF4E1 antibody, which detects eIF4E1a (both an alternatively spliced isoform L,
eIF4E1aL, and the canonical isoform, eIF4E1a) and eIF4E1b. (b) Analysis of binding recombinant proteins XeIF4E1a and
XeIF4E1b to GTP-Sepharose, m7GTP-Sepharose and m7GpCH2ppA-Sepharose by 15% SDS-PAGE and Coomassie
Blue staining. (c) The structures of GTP-Sepharose, m7GTP-Sepharose and m7GpCH2ppA-Sepharose are shown.
398 Cap-Binding Ability of eIF4E1bdifference in sequence between eIF4E1a and
eIF4E1b proteins distinguishes their affinity to the
cap, as well as specificity toward selected cap
analogues. This is evidenced by lower stabilization
of N7-methylguanine and weaker binding of the
phosphate chain by eIF4E1b that results in 3-fold
weaker cap-binding affinity. Our studies showed that
loops, S1-S2, S3-S4, S5-S6 and S7-S8, makesubstantial contributions to eIF4E–cap complex for-
mation because their flexibility enables local structural
changes. Binding m7GTP to eIF4E brings about
conformational rearrangements along with residues
that compose those loops and directly interact with
ligand (Fig. 2b) [21]. Our sequence analysis revealed
that residues that are strongly conserved in vertebrate
eIF4E1a but differ from those in eIF4E1b proteins in
399Cap-Binding Ability of eIF4E1bphysicochemical properties and/or size are found in
those flexible regions. Mutations of six of these
positions in XeIF4E1a to those found in XeIF4E1b
(E101S/K102R/S195A/M82S/T206L/T207S; XeI-
F4E1a numbering) reduce protein binding up to 50%
and make XeIF4E1a protein resemble XeIF4E1b in
binding N7-methylmononucleotides, clearly showing
that these residues modulate cap binding. Surprising-
ly, unlike eIF4E1a, eIF4E1b proteins show higher
affinity toward benzyl derivative, even though there is
no amino acid change in the hydrophobic vicinity of
bn7G compared to eIF4E1a, suggesting further local
rearrangements also in the protein's core.
The N7-benzyl derivatives are of interest as a
potential anticancer therapeutic. In this approach,
they are employed to inhibit the eIF4E1a–5′ mRNA
cap interaction in oncogenic cells with increased
eIF4E1a expression [41,42]. Cai et al. showed that
benzyl or p-chlorobenzyl for methyl substitutions at the
N7 position of guanine significantly increased the
inhibitory potency of themonophosphates (IC50 values
are 382 μM, 113 μMand 51 μM for m7GMP, bn7GMP
and p-Cl-bn7GMP, respectively) but not of the diphos-
phates (IC50 are 7.50 μMand 6.76 μM form
7GDPand
p-Cl-bn7GDP, respectively) [43]. The resolved struc-
tures of human eIF4E1awith bn7GMPor p-F-bn7GMP
showed that both benzyl and para-fluorobenzyl groups
accommodate in the hydrophobic part of the cap-bind-
ing pocket and form additional favorable protein
contacts to partly compensate for loss of β and γ
phosphates [32]. Indeed, later, Ghosh et al. revealed
that bn7GMP binds eIF4E1a 10-fold higher than the
methylated counterpart, m7GMP (Kd = 0.8 μM for
bn7GMP and Kd = 7.5 μM for m
7GMP) [44]. By
contrast, in the case of the diphosphate benzyl
derivative, bn7GDP (this study; Table 1), or the
dinucleotides bn7GpppG and bn7GppppG [45], no
increase in cap-binding affinity to eIF4E1a was
observed. This suggests that the presence of tightly
bound phosphate groups with protein could introduce
some constraints for interaction of the benzyl group
with eIF4E1a but not with eIF4E1b (Table 1).
Interestingly, the benzyl dinucleotide bn7GpppG
incorporates into mRNA during in vitro transcription
with similar efficiency as the anti-reverse cap
analogue (m7,3′OGpppG) with a 3′O position blocked
by a methyl group to force incorporation only in the
correct orientation [39,45]. This result and the fact
that both dinucleotide cap analogues, bn7GpppG
and m7,3′OGpppG, display higher inhibitory potency
and translational efficiency compared with
m7GpppG [39,45] suggest that the benzyl for methyl
substitution at N7 position of guanine is favorably
recognized by eIF4E1a in the rabbit reticulocyte
lysate system (RRL). Although there is no consis-
tency in the influence of the benzyl substitution at N7
position in binding affinity to eIF4E1a (this study and
Refs. [44] and [45]), all benzyl derivatives act as
efficient inhibitors in model biological systems (RRLand zebrafish embryo cells) compared with their
methylated counterparts [43–45]. bn7GMP, applied
in lung, breast cancer and malignant mesothelioma
cells as a membrane-permeable prodrug called
4Ei-1 [which is converted into the active compound
in cells—bn7GMP—by the histidine triad nucleoti-
de-binding protein 1 (Hint1)], suppresses malignant
phenotypes and chemosensitizes cells to non-toxic
levels of the cytotoxic drugs such as gemcitabine or
pemetrexed [46,47].
Other non-canonical eIF4E proteins such as 4EHP
(eIF4E2) or eIF4E3 also show lower binding to the
cap structure, though the difference in association
constants of these proteins for mononucleotide cap
analogues relative to eIF4E1a reaches 2 orders of
magnitude [10,11,20]. They share the same general
fold of a central curved β-sheet flanked by three
α-helices at their convex site, but unlike eIF4E1a,
they differ in cap binding slot arrangements that are
also modulated by loop residues. In 4EHP, stacking
interactions with m7Gua are realized by the aromatic
rings of Tyr78 and Trp124 but the length and
composition of the loops in which they are located
results in unfavorable ring orientation and conse-
quently contributes to its considerably weaker cap
interaction. In eIF4E3, Trp98 and Cys52 and
residues of the loop preceding the small helix
containing Cys52, specifically Ser43, Leu44,
Pro45, Ala47 and Ala49 have direct contact with
m7Gua. In all eIF4E proteins, contact with the
phosphate chain is mediated by a network of polar
and charged amino acids (eIF4E1a/1b: Asp90,
Arg112, Arg157 and Lys162; eIF4E2: His110,
Lys134, Arg138 and Arg174; eIF4E3: Arg152,
Lys192 and Arg 84). The C-terminal loop that varies
in different eIF4E subfamilies, though is quite evolu-
tionary conserved within one, exerts considerable
influence on stabilization of interactions with the
phosphate chain and the second cap nucleotide
and, uniquely in eIF4E3, has also contact with the
ribose ring. Nevertheless, even in the context of these
distinct features of cap binding by class I, II and III
eIF4E proteins, they all, so far, efficiently discriminate
between m7G and unmodified guanine [10,11,20].
Interestingly, recombinant human DcpS, a decap-
ping enzyme, like eIF4E1b, also only binds a cap
analogue well when separated by the same linker
from Sepharose [40]. In this case, the binding
capacity of this matrix was likely increased by the
incorporation of a dinucleotide analogue, based on
the structural data showing that hDcpS interacts not
only with N7-methylguanosine but also with the
second base of the cap structure [48].
eIF4E1b, cap binding and translational control in
early development
Ourextensive biophysical analysis of the cap-binding
properties of eIF4E1b proteins was prompted by our
400 Cap-Binding Ability of eIF4E1bearlier work and those of others of the role of these
proteins in translational regulation in early development
(see Introduction). In these studies, cap affinity,
assessed by monitoring binding of recombinant or of
oocyte lysate proteins to cap-Sepharose, was estimat-
ed to be very low, as only weak if any binding was
detected [15,17]. This was surprising to an extent, as,
first, eIF4E1b sequences are very similar to those of
eIF4E1a proteins and, second, the closed-loop model
of a repressed maternal mRNA invokes eIF4E1b
bound both to the cap and to an eIF4E-binding protein
such as 4E-T inhibiting translation [4,7]. Moreover,
4EHP, a class II eIF4E2, considerably less related to
eIF4E1a than is eIF4E1b and that binds the cap 30- to
100-fold less well than eIF4E1a [20], nevertheless
performs the same functions as those proposed for
eIF4E1b (see Introduction; see Ref. [49]). Weak cap
binding by these proteins may allow their release from
repressed mRNAs during meiotic maturation, for
example, and would not inhibit general protein
synthesis.
Our present study demonstrates that eIF4E1b
possesses distinct features of cap binding to eIF4E,
and it is pertinent to considerwhether thesedifferences,
particularly our prediction that its cap cavity is more
flexible, possibly reflect changes to the cap structure in
oocytes and eggs. Unfortunately, it is technically
difficult to assess the state of the cap on maternal
mRNAs, though a study employing microinjected
reporter mRNAs and cap analogues concluded
that the activity of a cytoplasmic guanine-7-methyl-
transferase increased substantially during oocyte
maturation and stimulated translation of an injected
mRNA bearing a nonmethylated GpppG cap. More-
over, the poly(A) tail and N7-methylation of reporter
mRNA stimulated translation synergistically though
independently at maturation [50]. While cytoplasmic
polyadenylation of maternal mRNA has been
extensively characterized and its role in translational
activation is understood to a considerable extent
[51,52], to our knowledge, there have been no
follow-up studies to that of Gillian-Daniel et al. [50],
and thus, the modification status of caps on maternal
mRNAs remains to be established. Though previously
suggested to stimulate translation at maturation [53],
cap ribose methylation was reported to be very
inefficient and not required for translational activation
by poly(A) [50]. We found no evidence that cap ribose
methylation on the first transcribed nucleotide en-
hanced cap binding by class I eIF4E proteins.
eIF4E1b and eIF4E-interacting proteins
eIF4E-binding proteins dictate the physiological
roles of cap-binding proteins. The principal example
is eIF4G, which in complex with eIF4E mediates
initiation of translation. The global mRNA inhibition of
translation is promoted by 4E-BP/eIF4E1a binding,
while translation of specific mRNA is negativelyregulated by the following partnerships: Bicoid-4EHP
[49], 4E-T-eIF4E1b [17], Cup-eIF4E [54,55], Pre-
p1-4EHP [56] and GIGYF2-4EHP [57]. 4E-T also
regulates eIF4E cellular distribution, as it can promote
transport of eIF4E1a to the nucleus [58] and it recruits
both eIF4E1a and eIF4E2 into processing bodies
(P-bodies) [7,59–61]. In all these cases, interaction of
eIF4E proteins to eIF4E-binding proteins is principally
mediated through a consensus eIF4E-binding motif
(YX4Lϕ or an extended variant YXYX4Lϕ), frequently
locatedwithin the N-terminal portion of eIF4E partners
[7,12]. Sequences downstream of the canonical
binding site in eIF4G and 4E-BP may also influence
interaction with eIF4E1a and may stabilize complex
formation [28,62–64]. Interestingly, the downstream
look-alike motif in vertebrate 4E-T, YX4VW, that binds
eIF4E1a, eIF4E2 and eIF4E1b, contributes differen-
tially to their 4E-T–eIF4E complex assembly [17,61].
Morita et al. reported that, in the case of GIGYF2
(GRB10 interacting GYF protein 2), its interaction with
4EHP is required for stabilization of both proteins in
human cells [57]. One of the best-characterized eIF4E
partners isDrosophilaCup that mediates translational
repression of oscar, nanos and gurkenmRNAs during
early development [19]. Both of its eIF4E-binding
sites, the canonical motif YTRSRLM and the non-ca-
nonical ELEGRLR, additively contribute to the overall
conformational stability of Drosophila eIF4E1. Inter-
estingly, Cup enhances almost 2-fold the cap-binding
protein's affinity to m7GDP [65], echoing the robust
increase shown by eIF4G [66]. It may be the case that
4E-T binding to eIF4E1b and eIF4E2 enhances their
affinity for the cap, though this remains to be
investigated. Previously, we observed that 4E-T
preferentially associates with eIF4E1b rather than
eIF4E1a in Xenopus oocytes [17,61], though the
underlying reason for this is not known. It is also
possible that eIF4E1b is phosphorylated or modified
by ubiquitin or ubiquitin-related peptides, as shown for
eIF4E2, which when modified with ISG15 binds the
cap more efficiently [67,68].
Altogether, our study implicates the role of
additional amino acids, located close to those that
bind the cap, in modulating cap affinity, and further
strengthen the evidence that C-terminal loop resi-
dues are also important for protein–cap interactions.
In the future, it will be undoubtedly interesting to
visualize the interactions of eIF4E1b with a capped
mRNA at a structural level, ideally in the presence of
the 4E-T-interacting peptide.
Materials and Methods
Cloning and mutagenesis
The cDNAs of Xenopus eIF4E1a, eIF4E1b and the
N-terminal truncated form, eIF4E1bΔN27, were amplified
by PCR from pGEM1 and pGEX-2T vectors [17] and
401Cap-Binding Ability of eIF4E1bcloned into the expression vector pET30a (Novagen)
between NdeI and BamHI restriction sites. The human
eIF4E1b gene in pUC57 vector (BIOMATIK) was similarly
subcloned into pET30a vector. Point mutations in Xenopus
eIF4E1a were introduced sequentially using the Quik-
Change Site-Directed Mutagenesis Kit (Stratagene) ac-
cording to the manufacturer's instructions. All constructs
were confirmed by sequencing. Oligonucleotides used for
cloning and mutagenesis are listed in Table S2.Sequence alignment and homology modeling
Multiple sequence alignment was performed using
CLUSTALW2. Protein sequences were downloaded from
the National Center for Biotechnology Information database
and eIF4E/4E-BP-Family Member Database [8]: Homo
sapiens 1a: NP_001959.1, 1b: NP_001092878.1; Mus
musculus 1a: AAH85087.1, 1b: Q3UTA9.1; X. laevis 1a:
NP_001089212.1, 1b: GenBank™ BQ398016 [8]; Xenopus
tropicalis 1a: CAJ83126.1, 1b: AAI54955.1 [8]; Danio rerio
1a: NP_571808.1, 1b: NP_571529.1; Bos taurus 1a:
NP_776735.2, 1b: XP_871211.1; Rattus norvegicus
1a: AAH87001.1, 1b: XP_003753002.1; Canis familiaris
1a: XP_544992.2, 1b: XP_546215.2; Gallus gallus 1a:
XP_420655.2, 1b: GenBank™ BX931053.2.
Comparative models of the structures of cap-free and
cap-bound X. laevis eIF4E1a and eIF4E1b were obtained
by the programMODELLER [69], based on the structure of
human cap-free eIF4E1a (PDB ID: 2GPQ) measured in
solution [21] and the crystal structure of mouse m7GpppG-
bound eIF4E1a (the second guanosine is not visible in the
structure; PDB ID: 1L8B [22]).
MODELLER generates protein structures by satisfaction
of spatial restraints with simultaneous optimisation of
CHARMM energies, conjugate gradients and molecular
dynamics with simulated annealing. Comparative models
were validated with PROCHECK [70] and WHAT_CHECK
[71] that study the geometry of the structures and with
VERIFY3D [72] that reports amino acid environmental
problems. All protein structure figures were generated
using PyMOL†
Protein expression and purification
Human and Xenopus eIF4E proteins were expressed in
the host strain Rosetta2(DE3) (Novagen). Culture of trans-
formed bacteria was induced by 0.5 mM isopro-
pyl-1-thio-β-D-galactopyranoside when the OD600 was ~1.
After 3 h of incubation at 37 °C, cells were harvested and
resuspended in lysis buffer [20 mM Hepes/KOH (pH 7.5),
100 mMKCl, 1 mMEDTA (ethylenediaminetetraaceticacid),
2 mM DTT and 10% (v/v) glycerol] and disrupted by
sonication. From the centrifuged lysate (30,000g for
30 min), the supernatant was removed and the pellet was
washed three times with wash buffer [1 M guanidine
hydrochloride, 20 mM Hepes/KOH (pH 7.2), 2 mM DTT
and 10% (v/v) glycerol]. The inclusion bodies were dissolved
in buffer containing 6 M guanidine hydrochloride, 50 mM
Hepes/KOH (pH 7.2), 10% (v/v) glycerol and 2 mMDTT, and
cell debris was removed by centrifugation (43,000g for
30 min). The protein (diluted to a concentration lower than
0.1 mg/mL)was refolded by one-step dialysis against 50 mM
Hepes/KOH (pH 7.2), 100 mM KCl, 0.5 mM EDTA and2 mM DTT and was then purified by ion-exchange chroma-
tography onaHiTrapSPHPcolumn (GEHealthcare) [20]. All
eIF4Eproteinswere elutedwith a linear gradient 0.1–1 MKCl
in 50 mMHepes/KOH (pH 7.2) andwere analyzed at once in
the fluorescent assay without freezing. We added 10%
glycerol to the Xenopus eIF4E1b fraction immediately after
elution. Additionally for Xenopus eIF4E1b, which possesses
more positively charged amino acids than eIF4E1a, the
dialysis step was preceded by partially removing the nucleic
acid from the protein fraction dissolved in 6 M guanidine
hydrochloride on silica membrane (Qiagen).
Purity of the collected proteins was assessed by
SDS-PAGE electrophoresis and their concentration was
determined spectrophotometrically using the extinction
coefficients calculated from amino acid compositions with
the ProtParam tool (ExPASy Server). These are ε280nm =
53,400 M− 1 cm − 1 for human eIF4E1a, ε280nm =
55,460 M − 1 cm − 1 for human eIF4E1b, ε280nm =
49,960 M−1 cm−1 for frog eIF4E1a and its mutated
forms and ε280nm = 51,450 M
−1 cm−1 for eIF4E1bΔN27.
Cap analogues and chemical agents
The cap analogues were synthesized as reported previ-
ously: m7GMP, m7GDP, m7GTP [73], m7GpppG, m7GpppA
[74], m7Gp4, m
7Gp5 [23], m
2,2,7GTP, et7GTP and bn7GTP
[75]. The cap analogue concentrations were determined
according to their extinction coefficients [33,43].
All chemical agents used in measurements were spec-
trophotometric grade and purchased from Sigma-Aldrich or
Roth.Spectroscopic measurements and numerical
data analysis
The time-synchronized titration method, originally
evolved by Niedzwiecka et al. [22,76], was used to
determine the binding affinity of proteins for cap analogues
with increasing cap concentration (ranging from 2 μM to
5 mM). For human eIF4E1a and eIF4E1b and also for
Xenopus eIF4E1a and its mutated forms, measurements
were carried out using 0.1 μM protein in 50 mM Hepes/
KOH (pH 7.2), 134.5 mM KCl, 0.5 mM EDTA and 1 mM
DTT. For Xenopus eIF4E1bΔN27, the concentration was
0.2 μM and glycerol was added to the buffer to 10% (v/v)
final concentration. Under these buffer conditions, eIF4E
fluorescence is observed in a range of 300–440 nm with a
maximum near 340–350 nm and m7GTP fluorescence
partially covers the same range, occurring at 320–440 nm
with a maximum near 380 nm (Fig. S2a). The gradually
increasing concentration of cap analogue quenches
protein fluorescence without shifting the spectrum maxi-
mum, while at high concentrations, the fluorescence signal
of free cap analogue dominates over the fluorescence from
other solution components including free eIF4E and eIF4E
in complex with cap (Fig. S2a). Fluorescence of measured
samples was excited at 280 nm (2.5 nm bandwidth) and
detected at 337 nm or 330 nm (4 nm bandwidth), thus
reducing the signal originated from the free cap analogues.
Measurements were carried out on a LS-55 spectrofluo-
rometer (Perkin Elmer Co.) using freshly prepared
proteins, and the fluorescence intensities were corrected
for sample dilution and the inner filter effect.
402 Cap-Binding Ability of eIF4E1bEquilibrium association constants (Kas) were determined
by fitting the theoretical dependence of fluorescence intensity
on the total concentration of the cap analogue to the
experimental data points, according to theequationdescribed
previously (see Ref. [22] and Fig. S2c). In the theoretical
model, we consider fluorescence of all solution components:
active ([Pact]) and inactive ([Pinact]) fraction of protein, protein
in complex with cap ([PactL]) and free ligand ([L]). Along with
Kas and the concentration of the active protein [P0
act], other
parameters such as fL and Δf = fPact − fPL are also gained
from the fit, where fL represents the fluorescence efficiency of
free cap analogue and Δf represents the difference between
the fluorescence efficiencies of the apo-protein and the
complex (Fig. S2c). In this model, the determined equilibrium
association constant does not dependent on the excitation or
the observation wavelength (Fig. S2).
The final Kas was calculated as a weighted average of
2–6 independent titrations with the weights taken as the
reciprocal of the numerical standard deviation squared.
Numerical, nonlinear least-squares regression analysis
was performed using Origin 6.0 (Microcal Software Inc.).
Obtained association constants were used to determine
the Gibbs free energy according to the standard equation
ΔG° = −RTlnKas.
The CD spectra were carried out on spectrometer
Chirascan™ CD (Applied Photophysics) in quartz cuvette
with optical length of 0.1 mm, in 50 mM phosphate buffer
and 125 mM NaClO4, at 20 °C.Cap-Sepharose binding assays
Cap-Sepharose binding assays were performed with
Xenopus oocyte lysates, with RRL extract in whichXenopus
eIF4E1 proteins were translated and with purified recombi-
nant proteins. Lysates were prepared from stage III and IV
oocytes as described previously [17], and aliquots in HKE
buffer [50 mMHepes (pH 7.4), 150 mMKCl, 0.5 mMEDTA,
0.5 mM ethylene glycol bis(β-aminoethyl ether) N,N
′-tetraacetic acid, 0.1 mMGTP and 14 mM β-mercaptoetha-
nol] were bound to GTP-Sepharose, m7GTP-Sepharose
and m7GpCH2ppA-Sepharose [40]. Following binding and
washing steps, we eluted bound proteins with 70 μM
m7GTP and then with SDS buffer (approximately 1% SDS
final). Aliquots of each fraction were subsequently analyzed
by SDS-PAGE and Western blotting, developed with an
anti-eIF4E1 rabbit antibody and ECL [17]. mRNAs encoding
the full-length Xenopus eIF4E1a and eIF4E1b proteins, as
well as a truncated version of Xenopus eIF4E1b missing
the first 27 amino acids, were transcribed and subse-
quently translated in vitro, as described previously [17].
The rabbit reticulocyte lysates were then bound to m-
7GTP-Sepharose (Pharmacia), and following several
washes, we eluted the bound proteins with GTP and
then m7GpppG [17]. Aliquots of each fraction were
analyzed by SDS-PAGE and autoradiography.
Purified recombinant proteins were bound to GTP-
Sepharose, m7GTP-Sepharose and m7GpCH2ppA-
Sepharose in 50 mM Hepes/KOH (pH 7.4), 150 mM
KCl, 0.5 mM EDTA and 1 mM DTT. Following binding
and washing steps, we eluted bound proteins with
100 μM m7GTP and then with 0.2% SDS buffer.
Aliquots of each fraction were subsequently analyzed
by SDS-PAGE and Coomassie Blue staining.Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jmb.2014.11.009.Acknowledgments
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